Loading company…
Sable Bio provides AI software for drug discovery and safety analysis.
Founded in 2023, Sable Bio develops software for biotech and pharmaceutical companies that analyzes structured and unstructured data, including clinical trials, for drug predictions and safety assessments. The company is based in London, UK, and was founded by Josh Almond-Thynne and Alex de Giorgio. In February 2026, it raised GBP 2.7 million in seed funding to develop its technology and data capabilities.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in